Aytu BioScience Inc (AYTU) USD0.0001

Sell:$2.30Buy:$2.38$0.02 (0.88%)

Prices delayed by at least 15 minutes
Sell:$2.30
Buy:$2.38
Change:$0.02 (0.88%)
Deal now
Prices delayed by at least 15 minutes
Sell:$2.30
Buy:$2.38
Change:$0.02 (0.88%)
Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

Aytu BioPharma, Inc. is a pharmaceutical company focused on advancing medicines for complex central nervous system (CNS) diseases. Its business is focused on the launch of EXXUA and its prescription pharmaceutical products sold primarily through third-party wholesalers and pharmacies and which primarily consists of two product portfolios. Its Attention Deficit Hyperactivity Disorder (ADHD) portfolio consists of Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets (Adzenys) , Cotempla XR-ODT, and METADATE CD, which are CNS stimulants indicated for the treatment of ADHD in patients. Its Pediatric portfolio consists of Karbinal ER (carbinoxamine maleate extended-release oral suspension), an extended-release first-generation antihistamine indicated to treat various allergic conditions including seasonal and perennial allergic rhinitis, vasomotor rhinitis, Poly-Vi-Flor, and Tri-Vi-Flor. EXXUA is indicated to treat depressive disorder (MDD) in adults.

Key people

Joshua R. Disbrow
Chief Executive Officer, Director
Ryan J. Selhorn
Chief Financial Officer, Treasurer, Corporate Secretary
Jarrett T. Disbrow
Chief Business Officer
Greg Pyszczymuka
Chief Commercial Officer
John A. Donofrio
Independent Chairman of the Board
Carl C. Dockery
Independent Director
Abhinav Jian
Independent Director
Vivian H. Liu
Independent Director
Click to see more

Key facts

  • Shares in issue
    10.19m
  • EPIC
    AYTU
  • ISIN
    US0547548588
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • Market cap
    $23.23m
  • Employees
    82
  • Exchange
    NASDAQ
  • Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.